研究单位：[1]Janssen Research & Development, LLC[2]Cancer Hospital Chinese Academy of Medical Sciences[3]Peking University First Hospital[4]TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
研究目的：
The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).
